Skip to main content

Affinity Asset Advisors, LLC

Position in CLDX — Celldex Therapeutics, Inc.

CIK 1773195 NEW YORK, NY

Position in CLDX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$26,047,000
+$10,187,000 QoQ
Shares Held
700,000
+40.0% QoQ
Ownership
0.891%
of shares outstanding
% of Portfolio
1.31%
of 13F equity value
Holder Rank
#30
of 252 holders
Holding Since
Dec 2020
21 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in CLDX Over Time

Shares Held

Position Value (USD)

Derivatives in CLDX

reported options exposure · as of Jun 30, 2022
CallValue
$3,909,200
CallShares
145,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names. CLDX ranks #20 (1.4% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in CLDX

Export CSV
22 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $26,047,000 700,000
2026-03-31 $15,860,000 500,000
2025-12-31 $9,506,000 350,000
2025-09-30 $7,761,000 300,000
2024-12-31 $252,497 9,992
2024-09-30 $4,248,750 125,000
2024-06-30 $17,594,554 475,400
2024-03-31 $21,404,700 510,000
2023-12-31 $15,864,000 400,000
2023-09-30 $4,128,000 150,000
2023-06-30 $2,952,961 87,031
2023-03-31 $1,799,000 50,000
2022-12-31 $4,902,700 110,000
2022-09-30 $2,248,800 80,000
2022-06-30 $1,078,400 40,000
2022-06-30 $3,909,200 145,000
2022-03-31 $4,257,500 125,000
2021-12-31 $3,864,000 100,000
2021-09-30 $2,167,914 40,154
2021-06-30 $1,672,000 50,000
2021-03-31 $2,678,000 130,000
2020-12-31 $1,314,000 75,000